CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Up 26.2% in December

CytomX Therapeutics, Inc. (NASDAQ:CTMX) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 5,540,000 shares, an increase of 26.2% from the November 30th total of 4,390,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is currently 4.8 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a report on Monday, November 11th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, CytomX Therapeutics has a consensus rating of “Hold” and a consensus price target of $5.77.

Institutional Investors Weigh In On CytomX Therapeutics

Several institutional investors have recently added to or reduced their stakes in CTMX. US Bancorp DE acquired a new stake in shares of CytomX Therapeutics in the 3rd quarter valued at about $40,000. XTX Topco Ltd raised its position in CytomX Therapeutics by 382.6% in the 2nd quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 48,033 shares during the last quarter. Forefront Analytics LLC lifted its position in CytomX Therapeutics by 206.7% during the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock worth $78,000 after buying an additional 43,176 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in CytomX Therapeutics by 96.6% during the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 40,309 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of CytomX Therapeutics in the 3rd quarter valued at about $104,000. 67.77% of the stock is owned by institutional investors.

CytomX Therapeutics Stock Performance

NASDAQ:CTMX opened at $1.02 on Tuesday. CytomX Therapeutics has a 52-week low of $0.83 and a 52-week high of $5.85. The company has a market cap of $79.82 million, a price-to-earnings ratio of 6.00 and a beta of 1.07. The stock’s fifty day moving average price is $1.05 and its two-hundred day moving average price is $1.18.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The company had revenue of $33.43 million during the quarter, compared to analysts’ expectations of $18.92 million. During the same period in the prior year, the business posted $0.04 EPS. On average, equities analysts predict that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.